Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck pifeltro (doravirine — HIV-1 NNRTI) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2025
171
Period ended Dec 31, 2025
Change on a year earlier
+4.9%
163 in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 171 | +4.9% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 163 | +14.8% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 142 | +20.3% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 118 | – | Form 10-K (filed 2025-02-25) ↗ |
Breakdown
What makes up pifeltro (doravirine — hiv-1 nnrti) — worldwide sales ($m)
- Pifeltro (doravirine — HIV-1 NNRTI) — U.S. sales ($M)111 · FY2025
- Pifeltro (doravirine — HIV-1 NNRTI) — International sales ($M)59 · FY2025
- Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide reported growth YoY (%)5.0% · FY2025
- Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide constant-currency (ex-exchange) growth YoY (%)4.0% · FY2025
Cite this data
StockData. (2026). Merck Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide sales ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_pifeltro
See every metric in the Merck KPI table. Data updated Oct 26, 2026.